Calendario›SNY›Amlitelimab · RIVER-ASTHMA
Amlitelimab · RIVER-ASTHMA
Long-term Safety and Efficacy Evaluation of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma Who Completed Treatment Period of Previous Amlitelimab Asthma Clinical Study
Ensayo de Sanofi en Asma.
Más ensayos de: Asma.
- Fase
- Fase 2
- Estado
- En marcha, sin reclutar
- Participantes
- 335
- Centros
- 68
- Fin del objetivo primario
- sep 2026
previstos
estimado por el promotor
Qué significa cada fase y cada estado.
Estudio de intervención, no aleatorizado, triple ciego. Comenzó en sep 2023.
Qué mide
Percentage of participants with treatment-emergent adverse events (From baseline up to Week 156 (EOS of LTS17510)) (del registro, en inglés)
Cómo lo describe el promotor
En el documentoEn inglés, del registroThis is a study of amlitelimab for the treatment of participants with moderate-to-severe asthma. The study will have a double-blind treatment period until Week 24 for each participant and an open-label treatment period where each participant will receive open-label amlitelimab from Week 24 onwards. The purpose of this study is to evaluate long-term safety, tolerability, and efficacy of amlitelimab for the treatment of adult participants with moderate-to-severe asthma who have previously been enrolled and completed the treatment period of the parent study. The study duration will be up to 156 weeks. The treatment duration will be up to 144 weeks. The number of visits will be 18.
Más ensayos de SNY
| Ensayo | Fase | Estado | Lectura de resultados |
|---|---|---|---|
| Avalglucosidase alfa · Mini-COMET | Fase 2 | En marcha, sin reclutar | sep 2019 (real) |
| Yellow fever vaccine | Fase 2 | En marcha, sin reclutar | may 2022 (real) |
| Yellow fever vaccine · VYF02 | Fase 2 | En marcha, sin reclutar | jun 2022 (real) |
| SAR441344 IV | Fase 2 | En marcha, sin reclutar | sep 2022 (real) |
| Meningococcal Polysaccharide | Fase 3 | En marcha, sin reclutar | mar 2023 (real) |
| Isatuximab IV · IRAKLIA | Fase 3 | En marcha, sin reclutar | nov 2024 (real) |
Todos los de SNY, en su ficha.
Ficha completa en ClinicalTrials.gov (NCT06033833), actualizada en may 2026.